Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
Ann Intern Med
.
2021 Sep;174(9):W66-W67.
doi: 10.7326/L21-0389.
Epub 2021 Jul 13.
Authors
Amir Qaseem
1
,
Jennifer Yost
2
,
Itziar Etxeandia-Ikobaltzeta
1
,
George M Abraham
3
,
Janet A Jokela
4
,
Matthew C Miller
5
,
Mary Ann Forciea
6
,
Linda L Humphrey
7
;
Scientific Medical Policy Committee of the American College of Physicians
;
Andrew Dunn
,
Rebecca Andrews
,
Ray Haeme
,
Mark P Tschanz
Collaborators
Scientific Medical Policy Committee of the American College of Physicians
:
Linda L Humphrey
,
Adam J Obley
,
Andrew Dunn
,
Robert M Centor
,
Elie A Akl
,
Rebecca Andrews
,
Thomas A Bledsoe
,
Mary Ann Forciea
,
Ray Haeme
,
Janet A Jokela
,
Devan L Kansagara
,
Maura Marcucci
,
Matthew C Miller
Affiliations
1
American College of Physicians, Philadelphia, Pennsylvania.
2
Villanova University, Villanova, Pennsylvania.
3
Saint Vincent Hospital-Worcester Medical Center, Worcester, Massachusetts.
4
University of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois.
5
Penn Medicine Radnor, Radnor, Pennsylvania.
6
Penn Medicine, Philadelphia, Pennsylvania.
7
Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon.
PMID:
34251904
PMCID:
PMC8297419
DOI:
10.7326/L21-0389
No abstract available
Publication types
Letter
Comment
MeSH terms
Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
COVID-19 Drug Treatment*
Humans
Physicians*
SARS-CoV-2
United States
Substances
remdesivir
Adenosine Monophosphate
Alanine